Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey

References

• O’BrienSGGuilhotFLarsonRAImatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med200334811994100412637609
   PubMed Web of Science ®Google Scholar
• Cherrier-De WildeSRackKVannuffelPDelannoyAHagemeijerAPhiladelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remissionLeukemia200317102046204814513056
   PubMed Web of Science ®Google Scholar
• HantschelOGrebienFSuperti-FurgaGThe growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABLCancer Res201272194890489523002203
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCAntoliniLMahonFXMulticenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinibJ Natl Cancer Inst2011103755356121422402
   PubMedGoogle Scholar
• BowerHBjorkholmMDickmanPWHoglundMLambertPCAnderssonTMLife expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general populationJ Clin Oncol201634242851285727325849
   PubMed Web of Science ®Google Scholar
• BocchiaMIppolitiMGozzettiACD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylateLeukemia200822242642817690698
   PubMed Web of Science ®Google Scholar
• ChuSMcDonaldTLinAPersistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatmentBlood2011118205565557221931114
   PubMed Web of Science ®Google Scholar
• BaccaraniMDeiningerMWRostiGEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood2013122687288423803709
   PubMed Web of Science ®Google Scholar
• SmithBDImatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effectsJ Natl Cancer Inst2011103752752921422404
   PubMedGoogle Scholar
• SausseleSRichterJHochhausAMahonFXThe concept of treatment- free remission in chronic myeloid leukemiaLeukemia20163081638164727133824
   PubMed Web of Science ®Google Scholar
• MeranteSOrlandiEBernasconiPCalatroniSBoniMLazzarinoMOutcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuationHaematologica200590797998115996937
   PubMed Web of Science ®Google Scholar
• RousselotPHuguetFReaDImatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 yearsBlood20071091586016973963
   PubMed Web of Science ®Google Scholar
• YhimHYLeeNRSongEKImatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular responseLeuk Res201236668969322398220
   PubMed Web of Science ®Google Scholar
• BrecciaMAlimenaGDiscontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemiaCancer Lett20143471222824508029
   PubMed Web of Science ®Google Scholar
• MahonFXReaDGuilhotJDiscontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialLancet Oncol201011111029103520965785
   PubMed Web of Science ®Google Scholar
• RossDMBranfordSSeymourJFSafety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyBlood2013122451552223704092
   PubMed Web of Science ®Google Scholar
• RousselotPCharbonnierACony-MakhoulPLoss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable diseaseJ Clin Oncol201432542443024323036
   PubMed Web of Science ®Google Scholar
• CrossNCWhiteHEColomerDLaboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemiaLeukemia2015295999100325652737
   PubMed Web of Science ®Google Scholar
• LeeSEChoiSYSongHYImatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID studyHaematologica2016101671772326888022
   PubMed Web of Science ®Google Scholar
• ImagawaJTanakaHOkadaMDiscontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trialLancet Haematol2015212e528e53526686407
   PubMed Web of Science ®Google Scholar
• ReaDNicoliniFETulliezMDiscontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI studyBlood2017129784685427932374
   PubMed Web of Science ®Google Scholar
• HughesTPHochhausAKantarjianHMSafety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyHaematologica20149971204121124532039
   PubMed Web of Science ®Google Scholar
• HochhausAMassziTGilesFJTreatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom studyLeukemia20173171525153128218239
   PubMed Web of Science ®Google Scholar
• VignaEGentileMGiagnuoloGLong-term molecular remission in Philadelphia-positive acute lymphoblastic leukemia elderly patient after dasatinib discontinuationLeuk Lymphoma201657102445244726879289
   PubMed Web of Science ®Google Scholar
• JiangQLiuZCZhangSXGaleRPYoung age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemiaJ Cancer Res Clin Oncol201614271539154727085529
   PubMed Web of Science ®Google Scholar
• PfirrmannMBaccaraniMSausseleSPrognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemiaLeukemia2016301485626416462
   PubMed Web of Science ®Google Scholar
• EfficaceFBaccaraniMBrecciaMInternational development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24Qual Life Res201423382583624026634
   PubMed Web of Science ®Google Scholar
• NoensLvan LierdeMADe BockRPrevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO studyBlood2009113225401541119349618
   PubMed Web of Science ®Google Scholar
• MarinDBazeosAMahonFXAdherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinibJ Clin Oncol201028142381238820385986
   PubMed Web of Science ®Google Scholar
• SanfordDKyleRLazo-LangnerAPatient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemiaCurr Oncol2014212e241e24924764709
   PubMed Web of Science ®Google Scholar
• BrecciaMEfficaceFSicaSAdherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patientsLeuk Res201539101055105926282944
   PubMed Web of Science ®Google Scholar
• UnnikrishnanRVeeraiahSManiSComprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinibClin Lymphoma Myeloma Leuk2016166366.e363371.e36327052853
   PubMed Web of Science ®Google Scholar
• EliassonLCliffordSBarberNMarinDExploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribedLeuk Res201135562663021095002
   PubMed Web of Science ®Google Scholar
• CellaDNowinskiCJFrankfurtOThe impact of symptom burden on patient quality of life in chronic myeloid leukemiaOncology201487313314725012261
   PubMed Web of Science ®Google Scholar
• KodamaYMorozumiRMatsumuraTIncreased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective surveyBMC Cancer20121215222530992
   PubMed Web of Science ®Google Scholar
• BoquimpaniCMSzczudloTMendelsonEBenjaminKMassziTAttitudes and perceptions of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) toward treatment-free remission (TFR)Blood2014124 abstract 4547
   Web of Science ®Google Scholar
• Villemagne SanchezLAO’CallaghanCGoughKPatient perceptions of treatment-free remission in chronic myeloid leukemiaLeuk Lymphoma201859240641528617066
   PubMed Web of Science ®Google Scholar
• MozosIBorzakGCarabaAMihaescuRArterial stiffness in hematologic malignanciesOnco Targets Ther2017101381138828424554
   PubMed Web of Science ®Google Scholar